Research shows combining KRAS inhibitors and immunotherapy could improve treatment for certain lung cancers, based on promising mouse studies.
Scientists have made a new discovery that could change how doctors treat a common type of lung cancer. They’ve found that using two different treatments together, one that targets a gene called KRAS and another that helps the immune system, might work better than using just one treatment alone. This could be really important because lung cancer is the number one cause of cancer deaths, and even with new treatments, lots of people still don’t get better.
The research was done in mice, so it’s not ready for doctors to use yet, but it gives them good ideas for tests they can do with people in the future. The KRAS gene is important because it tells cells when to grow and when to stop, and changes in this gene are found in many lung cancers. Recently, the FDA said it was okay to use a new drug that targets KRAS in patients with a certain type of lung cancer. But even with this drug, not everyone gets better, and sometimes the cancer stops responding to the treatment.
That’s why researchers are excited about combining the new KRAS drug with another type of treatment called immune checkpoint blockade, which helps the immune system attack cancer. Their experiments showed that in mice, this combo worked well, but only in some of them. This means doctors might need to figure out which patients are the best ones to try this new combo on, which could help more people survive lung cancer in the future.